Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation

被引:28
作者
Cholongitas, Evangelos [1 ]
Papatheodoridis, George V. [2 ]
机构
[1] Aristotle Univ Thessaloniki, Hippokration Gen Hosp Thessaloniki, Sch Med, Dept Internal Med 4, Thessaloniki 54642, Greece
[2] Univ Athens, Sch Med, Laiko Gen Hosp Athens, Dept Gastroenterol, GR-11527 Athens, Greece
关键词
Hepatitis B virus; Liver transplantation; Hepatitis B virus immunoglobulin; Antivirals; Lamivudine; Adefovir; Entecavir; Tenofovir; Telbivudine; Resistance; TENOFOVIR DISOPROXIL FUMARATE; LONG-TERM LAMIVUDINE; ADEFOVIR DIPIVOXIL; IMMUNE GLOBULIN; VIRUS-INFECTION; DECOMPENSATED CIRRHOSIS; NUCLEOS(T)IDE ANALOGS; GRAFT REINFECTION; NAIVE PATIENTS; PROPHYLAXIS;
D O I
10.3748/wjg.v19.i48.9189
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The progress in treatment against hepatitis B virus (HBV) with the development of effective and well tolerated nucleotide analogues (NAs) has improved the outcome of patients with HBV decompensated cirrhosis and has prevented post-transplant HBV recurrence. This review summarizes updated issues related to the management of patients with HBV infection before and after liver transplantation (LT). A literature search using the PubMed/Medline databases and consensus documents was performed. Pre-transplant therapy has been initially based on lamivudine, but entecavir and tenofovir represent the currently recommended first-line NAs for the treatment of patients with HBV decompensated cirrhosis. After LT, the combination of HBV immunoglobulin (HBIG) and NA is considered as the standard of care for prophylaxis against HBV recurrence. The combination of HBIG and lamivudine is related to higher rates of HBV recurrence, compared to the HBIG and entecavir or tenofovir combination. In HBIG-free prophylactic regimens, entecavir and tenofovir should be the first-line options. The choice of treatment for HBV recurrence depends on prior prophylactic therapy, but entecavir and tenofovir seem to be the most attractive options. Finally, liver grafts from hepatitis B core antibody (anti-HBc) positive donors can be safely used in hepatitis B surface antigen negative, preferentially anti-HBc/anti-hepatitis B surface antibody positive recipients. (C) 2013 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码:9189 / 9197
页数:9
相关论文
共 50 条
[41]   Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: A systematic review [J].
Chen, Jie ;
Yi, Liping ;
Jia, Ji Dong ;
Ma, Hong ;
You, Hong .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 (05) :872-879
[42]   Review article: preventing hepatitis B graft infection in hepatitis B patients after liver transplantation: immunoglobulin vs anti-virals [J].
Park, James S. ;
Gayam, Vijay ;
Pan, Calvin Q. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (06) :944-954
[43]   Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management [J].
Chauhan, Ranjit ;
Lingala, Shilpa ;
Gadiparthi, Chiranjeevi ;
Lahiri, Nivedita ;
Mohanty, Smruti R. ;
Wu, Jian ;
Michalak, Tomasz I. ;
Satapathy, Sanjaya K. .
WORLD JOURNAL OF HEPATOLOGY, 2018, 10 (03) :352-370
[44]   Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management [J].
Ranjit Chauhan ;
Shilpa Lingala ;
Chiranjeevi Gadiparthi ;
Nivedita Lahiri ;
Smruti R Mohanty ;
Jian Wu ;
Tomasz I Michalak ;
Sanjaya K Satapathy .
World Journal of Hepatology, 2018, (03) :352-370
[45]   Liver transplantation for hepatitis B [J].
Han, SHB ;
Martin, P .
HEPATOLOGY RESEARCH, 2004, 29 (04) :193-201
[46]   Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy [J].
Zhang, F. K. ;
Zhang, Y. ;
Zhang, J. Y. ;
Jia, J. D. ;
Wang, B. E. .
TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (06) :549-552
[47]   Clinical study on prevention of HBV re-infection by entecavir after liver transplantation [J].
Cai, Chang-jie ;
Lu, Min-qiang ;
Chen, Ying-hua ;
Zhao, Hui ;
Li, Min-ru ;
Chen, Gui-hua .
CLINICAL TRANSPLANTATION, 2012, 26 (02) :208-215
[48]   Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation [J].
Congly, Stephen E. ;
Burak, Kelly W. ;
Coffin, Carla S. .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (04) :429-436
[49]   Management of hepatitis C infection after liver transplantation [J].
Alsatie, Mazen ;
Chalasani, Naga ;
Kwo, Paul Y. .
DRUGS, 2007, 67 (06) :871-885
[50]   Impact of Virologic Breakthrough and HBIG Regimen on Hepatitis B Recurrence After Liver Transplantation [J].
Degertekin, B. ;
Han, Steven-Huy B. ;
Keeffe, E. B. ;
Schiff, E. R. ;
Luketic, V. A. ;
Brown, R. S., Jr. ;
Emre, S. ;
Soldevila-Pico, C. ;
Reddy, K. R. ;
Ishitani, M. B. ;
Tran, T. T. ;
Pruett, T. L. ;
Lok, A. S. F. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (08) :1823-1833